BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
Business Wire•19/10/2026•06:00 ET
0
Key Highlights
- ➤BeOne (ONC) will present four priority solid-tumor programs at ESMO 2026.
- ➤BGB-B2033 advances with Phase 1 dose-optimization data in previously treated advanced HCC.
- ➤BG-C477 reports first-in-human Phase 1 data in heavily pretreated advanced NSCLC.
- ➤BGB-58067 presents first-in-human data in MTAP-deficient advanced tumors.
- ➤HERIZON-GEA-01 delivers second interim data for zanidatamab plus chemotherapy with or without TEVIMBRA.
Expert Statements
Mark Lanasa, Chief Medical Officer, Solid Tumors at BeOne
“2026 has been an inflection year for our solid tumor portfolio. Across major medical congresses, we have demonstrated proof of concept for five priority programs, while rapidly advancing these assets toward pivotal development. At ESMO, that progress is visible in pipeline data spanning our three strategically focused disease areas, breast, lung, and gastrointestinal cancers, alongside further evidence supporting TEVIMBRA, including updated Phase 3 data in combination with ZIIHERA in HER2+ gastroesophageal adenocarcinoma. Together, the reach of TEVIMBRA and a pipeline advancing at scale position BeOne to change the game in solid tumor oncology.”
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipeline
Get started
Create a free account to read the full story.